Clearmind Medicine (CMND) announced a historic milestone: the first participant has been dosed with CMND-100, its proprietary MEAI-based oral drug candidate, in its Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder, AUD. This marks the first time a patient has received Clearmind’s innovative treatment in a clinical setting, a critical step toward the development of a potential new therapy for millions affected by AUD worldwide. The dosing follows the Company’s announcement on June 5, 2025, of the enrollment of the first participant in the trial, which is being conducted at leading clinical sites, including Yale School of Medicine’s Department of Psychiatry and Johns Hopkins University School of Medicine in the United States as well as Tel Aviv Sourasky Medical Center and Hadassah-University Medical Center in Jerusalem.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Clearmind Medicine expands global clinical trial targeting AUD market
- Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
- Clearmind Medicine enrolls first patient in Phase I/IIa trial for CMND-100
- Mike Davis to become CDER deputy director, Pink Sheet’s Gingery says
- Clearmind notes partnership with political firm to promote psychedelics